Medicare Part D Rules and Cost-Containment Regulations will Limit Uptake of
New Drugs for the Treatment of Parkinson's Disease
Monday June 12, 8:00 am ET
Promising New Therapies Will Have to Differentiate Themselves in Order to
Unseat Market-Leading Drugs, According to a New Report from Decision
Resources
WALTHAM, Mass., June 12 /PRNewswire/ -- Decision Resources, Inc., one of the
world's leading research and advisory firms for pharmaceutical and health
care issues, finds that Medicare rules in the United States and new
regulations in Europe and Japan will cause physicians to alter their
prescribing habits and will limit the uptake of new therapies for
Parkinson's disease.
The new Pharmacor report entitled Parkinson's Disease finds that Medicare
Part D rules in the United States and cost-containment regulations in Europe
and Japan have changed the reimbursement environment, making it very
difficult for new treatments to unseat the dominant players in the market,
including Bristol-Myers Squibb's Sinemet IR and CR, Boehringer Ingelheim's
Mirapex, and GlaxoSmithKline's Requip.
However, novel therapies will launch with new mechanisms of action that
treat nondopaminergic symptoms of Parkinson's disease and motor
complications caused by Sinemet treatment. These promising emerging
therapies such as Merck KGaA's sarizotan and Kyowo Hakko Kogyo's
istradefylline, will provide medical benefit to patients and will earn
significant sales.
"The cost vigilance of payers will dramatically limit the pricing,
reimbursement, and uptake of new drugs that do not differentiate themselves
from earlier-to-market competitors and their generic alternatives," said
Julie Kerner, Ph.D., analyst at Decision Resources, Inc. "Only new drugs
that can show better efficacy or novel mechanisms of action compared with
currently-available Parkinson's disease therapies will succeed."
About Parkinson's Disease
Parkinson's disease is characterized by motor symptoms such as tremor,
muscle rigidity, gait dysfunction, and postural instability. In the major
pharmaceutical markets, Parkinson's disease ranks as one of the most common
chronic, progressive motor system disorders in the elderly. In the United
States, the prevalence of the disease is 7.4 cases per 1,000 people.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a world
leader in market research publications, advisory services, and consulting
designed to help clients shape strategy, allocate resources, and master
their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
[log in to unmask]
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
